The present invention concerns a method of treatment or prevention of myocardial ischemia-reperfusion injury by diagnosing that a person is in need of treatment or prevention of myocardial ischemia-reperfusion injury and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
本发明涉及一种治疗或预防心肌缺血再灌注损伤的方法,通过诊断一个人需要治疗或预防心肌缺血再灌注损伤,并通过与
雌激素受体ER-α、
雌激素受体ER-β或ER-α和ER-β
雌激素受体中的一个或两个相互作用来给予调节NF-kB转录因子的
配体的治疗有效量,其中刺激
肌酸激酶的作用显著缺乏。在某些优选实施例中,给药基本上不具有子宫营养活性。